Xenon Pharma Tumbles On Azetukalner Psychiatry Trial Enrollment Pause; Files Focal Seizure NDA

Xenon Pharmaceuticals shares plunged more than 25% after hours after the company voluntarily paused new patient enrollment in ongoing Phase 3 studies of azetukalner for major depressive disorder. The enrollment halt introduces material clinical-development and regulatory uncertainty for the neuroscience-focused biotech's key late-stage program.